The latest developments, IND, bringing together highly recognized professionals with prestigious reputations and substantial wealth seem a mismatch with a volatile sub-penny micro-cap stock.
The five men who control the voting power for SVFC must be considering other ways of financing progress besides the issuing of more stock. About 3 years ago the PPS was near $5. IMO financial practices of the past couple years cannot be relied upon for future ventures.
New IP and clinical trials, an expansion of RegenMed centers, networks with varied professionals, those blue sky items yet to receive form and financing -- all need money muscle on the conceptual bones. Many will be watching to see how this potential legacy venture takes shape.
Not everyone with high wealth achieves commensurate significance. SVFC could be attractive as a global health blockbuster.
